Role of von Willebrand factor in tumor metastasis

Terraube, Virginie; Marx, Isabelle; Denis, Cécile V.

doi:10.1016/s0049-3848(07)70132-9

Cited by 83 publications

(80 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When the platelet amount is reduced, metastasis is reduced as well. Recent studies have indicated that vWF, in particular, can function as a promoter of tumor cell metastasis [43,44]. For example, the B16-BL6 melanoma cell transplantable tumor cell line has been demonstrated to adhere to vWF through the membrane-expressed integrin αVβ3.…”

Section: The Biological Effects Of Vwfmentioning

confidence: 99%

von Willebrand Factor: More Than a Regulator of Hemostasis and Thrombosis

Luo

Yang

et al. 2012

Acta Haematol

View full text Add to dashboard Cite

von Willebrand factor (vWF) was first identified as an adhesive glycoprotein involved in hemostasis by Zimmermann in 1971. Since then, vWF has been shown to play a vital role in platelet adhesion, platelet binding to collagen and factor VIII protection. Recent studies have implicated vWF as a regulator of angiogenesis, smooth muscle cell proliferation, tumor cell metastasis and crosstalk in the immune system. In this review, we will discuss the aspects of vWF structure that facilitate its biological effects and speculate on its newly discovered and hypothesized roles in the pathogenesis of several diseases.

show abstract

Section: The Biological Effects Of Vwfmentioning

confidence: 99%

von Willebrand Factor: More Than a Regulator of Hemostasis and Thrombosis

Luo

Yang

et al. 2012

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…Many tumor cell lines express themselves the same integrins that are normally found on platelets, namely GPIb and αIIbβ3 (GPIIb/IIIa), adding to their malignant potential (Trikha et al, 1998;Chen et al, 1997). Therefore, it is not surprising to consider an independent role for their ligand vWF in tumor metastasis (Terraube et al, 2007).…”

Section: Iii-d Platelet Integrinsmentioning

confidence: 99%

Platelets, Coagulation and Cancer: Multifaceted Interactions

Goubran

Burnouf²

2012

American Medical Journal

View full text Add to dashboard Cite

Approach: Literature review of the multifaceted interactions between platelets, coagulation and cancer. Results: Over the years, the links existing between cancer development, progression and occurrence of metastasis on one side and coagulation on the other have become obvious. Tumors seems to activate platelets whereas, platelets, on the other hand, through their capacity to activate and release soluble factors and microparticles, interact with tumor cells and influence immune regulation. They appear to be key regulators of many cancer events. Furthermore, coagulation with its different facets also interplays and significantly crosstalks with malignancy. The objectives of this article are to review the mechanisms through which cancer interacts with platelets and the coagulation, triggering thrombosis and the role played by platelets and coagulation factors in the regulation of cancer and to underline the perspectives that are now open in the development of novel diagnostic tools and new cancer treatment strategies. Conclusion/Recommendations: Challenging issues and unresolved questions still need to be addressed to understand the complexity existing between coagulation factors and platelet components and the different stages of cancer progression. Recent discoveries are leading clinicians to consider new therapeutic applications of anticoagulant therapies or new drugs targeting specific platelet functions in cancer patients' management. Furthermore, markers of coagulation and platelet activity may prove to serve as biomarkers for dormant tumors.

show abstract

“…In total, ~66% of the variations in VWF Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS-13 in patients with lung cancer plasma levels are associated with mutations, and 30% of these are associated with the effect of the ABO blood group (10). Increased levels of VWF and FVIII and impaired activity of ADAMTS-13 have been demonstrated in patients with metastasizing and malignant tumors (12). The majority of studies have not focused on the levels of VWF, FVIII and ADAMTS-13 in patients with lung cancer; however, Martini et al (13) reported that VWF antigen levels are not substantially altered in patients with non-small cell lung cancer.…”

Section: Introductionmentioning

confidence: 99%

Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS-13 in patients with lung cancer

et al. 2017

View full text Add to dashboard Cite

Abstract. Coagulative and fibrinolytic disorders appear to be associated with the development of lung cancer. The aim of the present study was to determine plasma levels of von Willebrand factor (VWF) and a disintegrin and metalloproteinase with a thrombospondin type 1 motif 13 (ADAMTS-13), and factor VIII (FVIII) activity, in association with O and non-O blood groups in patients with lung cancer. Plasma levels of VWF and ADAMTS-13, and FVIII activity were measured in 115 patients with lung cancer and 98 healthy subjects. Phenotyping of the ABO blood groups was also performed for the two groups. Significantly increased VWF levels and FVIII activity, as well as significantly decreased ADAMTS-13 levels, were observed in patients with distant metastasis as compared with those without distant metastasis and the healthy controls. Plasma VWF levels and FVIII activity were significantly increased in subjects with non-O type blood compared with those with type O blood in the two groups. However, a significant decrease in ADAMTS-13 levels was observed only in the control group among those with non-O type blood, compared with those with type O blood. The results of the present study indicate that increased VWF and decreased ADAMTS-13 levels facilitate the invasiveness and metastasis of lung cancer. Non-O blood groups constitute a risk factor for increased VWF and FVIII in plasma. Continued monitoring of VWF and ADAMTS-13 levels, and of FVIII activity in patients with lung cancer with distinct blood groups may help to minimize the incidence of thrombotic events and improve assessment of disease progression.

show abstract

Role of von Willebrand factor in tumor metastasis

Cited by 83 publications

References 31 publications

von Willebrand Factor: More Than a Regulator of Hemostasis and Thrombosis

von Willebrand Factor: More Than a Regulator of Hemostasis and Thrombosis

Platelets, Coagulation and Cancer: Multifaceted Interactions

Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS-13 in patients with lung cancer

Contact Info

Product

Resources

About